Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 15/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373628 | 0.93 | CXCR3 (0.69) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5456451 | 0.92 | CXCR3 (0.77) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14470441 | 0.91 | CXCR3 (0.65) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14373615 | 0.90 | CLK2 (0.67) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14373627 | 0.90 | BRSK1 (0.64) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14373639 | 0.89 | CXCR3 (0.64) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14373643 | 0.87 | CXCR3 (0.62) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14373323 | 0.86 | CXCR3 (0.84) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL14373632 | 0.85 | CXCR3 (0.66) | CXCR3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5455024 | 0.85 | CXCR3 (0.73) | CXCR3MEN1KMT2ACLK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885MEN1 614/4885KMT2A 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.